Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Break Below Two Hundred Day Moving Average – What’s Next?

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $13.24 and traded as low as $11.00. Enanta Pharmaceuticals shares last traded at $11.41, with a volume of 293,410 shares trading hands.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, October 11th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Thursday, October 15th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Enanta Pharmaceuticals Trading Down 3.1%

The firm has a market cap of $329.35 million, a PE ratio of -4.69 and a beta of 0.96. The stock’s 50 day moving average price is $12.83 and its 200 day moving average price is $13.23.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. Analysts forecast that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC bought a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $53,252,000. BlackRock Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at $47,304,000. ADAR1 Capital Management LLC acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $19,603,000. Spruce Street Capital LP purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter worth $15,873,698. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $2,231,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.